Modified Botulinum Neurotoxin Heavy Chain for Nerve Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating neuromuscular disorders using clostridial neurotoxins, such as botulinum toxin, face challenges including short duration of efficacy, immunogenicity, and the need for frequent injections due to antibody formation, as well as the presence of non-toxic bacterial proteins that can act as immuno-adjuvants, leading to immune responses.
Innovation Solution
A modified transport protein (Trapo) is developed by altering the heavy chain of the Clostridium botulinum neurotoxin, which binds to nerve cells with higher or lower affinity and altered neurotoxicity, and is designed to evade neutralizing antibodies, allowing for increased efficacy and reduced immune response by modifying surface-exposed amino acids in the ganglioside- and protein-receptor binding pockets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If clostridial neurotoxins are used to treat neuromuscular disorders, then therapeutic effect is achieved, but duration of efficacy is short and frequent injections are required
Solution Approach 1:
The patent modifies the heavy chain of the neurotoxin by altering amino acid sequences, particularly in the receptor binding domain, to change the kinetic parameters of toxin-receptor interaction. This includes extending the half-life of the toxin at the injection site and reducing the rate of internalization, thereby prolonging therapeutic effect without requiring frequent re-administration
2Reliability
If clostridial neurotoxins are used for treatment, then therapeutic effect is achieved, but immunogenicity occurs leading to antibody formation
Solution Approach 1:
The patent separates the therapeutic light chain from the immunogenic heavy chain, using only the light chain or modified versions thereof. This extraction of the essential therapeutic component while removing the problematic heavy chain eliminates the source of immunogenicity while preserving the ability to cleave SNARE proteins and inhibit neurotransmitter release
Solution Approach 2:
The patent creates simplified versions or analogs of the neurotoxin light chain that replicate the essential proteolytic function without the immunogenic heavy chain structure. These copied functional elements maintain therapeutic efficacy while avoiding antibody formation against the full toxin structure
3Reliability
If bacterial proteins are present in the treatment, then neurotoxin delivery is achieved, but immuno-adjuvant effects occur causing immune responses
Solution Approach 1:
The patent removes all bacterial proteins and components from the treatment formulation, using only the purified neurotoxin light chain or its modified versions. This extraction eliminates immuno-adjuvant effects while maintaining the core therapeutic function of inhibiting neurotransmitter release through proteolytic cleavage of SNARE proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified transport protein achieves enhanced affinity and absorption into nerve cells, prolonging the duration of therapeutic effect while minimizing antibody formation, thus allowing for lower dosages and reduced frequency of administration, thereby addressing the limitations of existing treatments.
Implementation Method 1
The transport protein is preferably absorbed by receptor-mediated endocytosis
Data Source
AI summary
The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.